Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Peter A. Ory"'
Autor:
Daniel G. Malone, Peter A. Ory, Alan J. Bridges, Frank M. Graziano, Judy Jicinsky, William D. Engber, Marcus Y. Chen
Publikováno v:
Arthritis & Rheumatism. 34:1116-1124
Mast cells were isolated by enzymatic digestion of synovium obtained from 48 patients with rheumatoid arthritis (RA) and 42 patients with osteoarthritis (OA). A significantly lower percentage of stainable synovial mast cells was obtained by tissue di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358008b3806e05a10b274d0d262f7619
https://doi.org/10.1002/art.1780340907
https://doi.org/10.1002/art.1780340907
Autor:
Stanley B, Cohen, Robin K, Dore, Nancy E, Lane, Peter A, Ory, Charles G, Peterfy, John T, Sharp, Désirée, van der Heijde, Lifen, Zhou, Wayne, Tsuji, Richard, Newmark, Michel, Zummer
Publikováno v:
Arthritis and rheumatism. 58(5)
Objective RANKL is essential for osteoclast development, activation, and survival. Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting its activity. The aim of this multicenter, randomized, double-blind, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d7ecb2ecc03415f736e4603851e6f8
https://pubmed.ncbi.nlm.nih.gov/18839011
https://pubmed.ncbi.nlm.nih.gov/18839011
Autor:
Christopher T. Ritchlin, Peter A. Ory, Philip J. Mease, Ernest Choy, Dafna D. Gladman, Eric H. Sasso, John T. Sharp, Renee J. Perdok
Publikováno v:
Arthritis and rheumatism. 56(2)
Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti–tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA). Methods Patients who c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e87f7dd242115884aeafd78f05dee4
https://pubmed.ncbi.nlm.nih.gov/17265483
https://pubmed.ncbi.nlm.nih.gov/17265483
Autor:
Serge Steinfeld, Eric Ruderman, Peter A. Ory, Dafna D. Gladman, John T. Sharp, Philip J. Mease, Renee J. Perdok, Christopher T. Ritchlin, M A Weinberg, Ernest Choy
Publikováno v:
Arthritis and rheumatism. 52(10)
Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA). Methods Patients with moderately to severely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1825dd3642707dcd79f26ed46cc3b114
https://pubmed.ncbi.nlm.nih.gov/16200601
https://pubmed.ncbi.nlm.nih.gov/16200601
Autor:
Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok, Eric H. Sasso
Publikováno v:
Arthritis & Rheumatism; Feb2007, Vol. 56 Issue 2, p476-488, 13p
Autor:
Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Eric M. Ruderman, Serge D. Steinfeld, Ernest H.S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok, Mark A. Weinberg
Publikováno v:
Arthritis & Rheumatism; Oct2005, Vol. 52 Issue 10, p3279-3289, 0p